医学と薬学　80/4　2023年4月号

出版社： 自然科学社
発行日： 2023-03-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 食道癌治療の進歩―早期癌から進行癌まで
電子書籍版： 2023-03-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　食道癌治療の進歩―早期癌から進行癌まで

    序文
    食道表在癌に対する内視鏡切除
    切除可能な食道癌に対する化学放射線療法の進歩
    切除可能局所進行食道癌に対する手術療法の進歩
    切除可能局所進行食道癌に対する術前治療の進歩
    切除不能局所進行食道癌に対する集学的治療の進歩
    進行再発食道癌に対する免疫チェックポイント阻害薬

    研究
    　人工膜を用いたテープ剤の製剤学的特性評価法に関する検討

    Diagnosis
    　自動化学発光酵素免疫分析装置Accuraseed による甲状腺自己抗体
    　　TgAb, TPOAb, TRAb 測定試薬の臨床性能評価
    　浸透圧分析装置オズモステーション2OM-6070の基礎的検討
    　HBs抗原測定試薬「アテリカ用B型肝炎ウイルス表面抗原キットケミルミQHBs抗原」の性能評価
    　SARS-CoV-2感染症診断におけるケミルミSARS-CoV-2Agの臨床的有用性の検討

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 食道癌治療の進歩 - 早期癌から進行癌まで】

P.339 掲載の参考文献
1) 国立研究開発法人国立がん研究センター : がん情報サービス.
 
2) Oyama T, Tomori A, Hotta K, et al : Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3 : S67-70, 2005.
PubMed
3) Akutsu Y, Uesato M, Shuto K, et al : The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma : a retrospective analysis of 295 patients. Ann Surg 257 : 1032-1038, 2013.
PubMed
4) Ishihara R, Arima M, Iizuka T, et al ; Japan Gastroenterological Endoscopy Society Guidelines Committee of ESD/EMR for Esophageal Cancer : Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 32 : 452-493, 2020.
PubMed
5) Oyama T, Inoue H, Arima M, et al : Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology : magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 14 : 105-112, 2017.
PubMed
6) Kadota T, Yano T, Kato T, et al : Prophylactic steroid administration for strictures after endoscopic resection of large superficial esophageal squamous cell carcinoma. Endosc Int Open 4 : E1267-1274, 2016.
PubMed
7) Miwata T, Oka S, Tanaka S, et al : Risk factors for esophageal stenosis after entire circumferential endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Surgical endoscopy 30 : 4049-4056, 2016.
PubMed
8) Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society : part 2. Esophagus 16 : 25-43, 2019.
PubMed
9) Kitagawa Y, Uno T, Oyama T, et al : Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society : part 1. Esophagus 16 : 1-24, 2019.
 
10) Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al : Endoscopic submucosal dissection : European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47 : 829-854, 2015.
PubMed
11) Fujishiro M, Yahagi N, Kakushima N, et al : Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol 4 : 688-694, 2006.
PubMed
12) Fujinami H, Hosokawa A, Ogawa K, et al : Endoscopic submucosal dissection for superficial esophageal neoplasms using the stag beetle knife. Dis Esophagus 27 : 50-54, 2014.
PubMed
13) Chaves DM, Maluf Filho F, de Moura EG, et al : Endoscopic submucosal dissection for the treatment of early esophageal and gastric cancer-initial experience of a western center. Clinics (Sao Paulo, Brazil) 65 : 377-382, 2010.
PubMed
14) Kanzaki H, Ishihara R, Ohta T, et al : Randomized study of two endo-knives for endoscopic submucosal dissection of esophageal cancer. Am J Gastroenterol 108 : 1293-1298, 2013.
PubMed
15) Miyamoto Y, Nonaka S, Oda I, et al : Safety and usefulness of endoscopic submucosal dissection for early esophageal cancers in elderly patients aged 80 years or older. Esophagus 18 : 81-89, 2021.
PubMed
16) Oyama T : Esophageal ESD : technique and prevention of complications. Gastrointest Endosc Clin N Am 24 : 201-212, 2014.
PubMed
17) Yoshida M, Takizawa K, Nonaka S, et al : Conventional versus traction-assisted endoscopic submucosal dissection for large esophageal cancers : a multicenter, randomized controlled trial (with video). Gastrointest Endosc 91 : 55-65.e2., 2020
 
18) Katada C, Muto M, Manabe T, et al : Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc 57 : 165-169, 2003
PubMed
19) Shi Q, Ju H, Yao LQ, et al : Risk factors for postoperative stricture after endoscopic submucosal dissection for superficial esophageal carcinoma. Endoscopy 46 : 640-644, 2014.
PubMed
20) Ono S, Fujishiro M, Niimi K, et al : Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy 41 : 661-665, 2009.
PubMed
21) Hanaoka N, Ishihara R, Takeuchi Y, et al : Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer : a controlled prospective study. Endoscopy 44 : 1007-1011, 2012.
PubMed
22) Hashimoto S, Kobayashi M, Takeuchi M, et al : The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc 74 : 1389-1393, 2011.
PubMed
23) Isomoto H, Yamaguchi N, Nakayama T, et al : Management of esophageal stricture after complete circular endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. BMC Gastroenterol 11 : 46, 2011.
PubMed
24) Takahashi H, Arimura Y, Okahara S, et al : A randomized controlled trial of endoscopic steroid injection for prophylaxis of esophageal stenoses after extensive endoscopic submucosal dissection. BMC Gastroenterol 15 : 1, 2015.
PubMed
25) Yamaguchi N, Isomoto H, Nakayama T, et al : Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc 73 : 1115-1121, 2011.
PubMed
26) 日本食道学会 (編) : 食道癌診療ガイドライン 2022年度版, 金原出版, 東京, 2022.
 
27) Ono S, Fujishiro M, Niimi K, et al : Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc 70 : 860-866, 2009.
PubMed
28) Toyonaga T, Man-i M, East JE, et al : 1,635 Endoscopic submucosal dissection cases in the esophagus, stomach, and colorectum : complication rates and long-term outcomes. Surgical endoscopy 27 : 1000-1008, 2013.
PubMed
29) Iwai N, Dohi O, Yamada S, et al : Prognostic risk factors associated with esophageal squamous cell carcinoma patients undergoing endoscopic submucosal dissection : a multi-center cohort study. Surg Endosc 36 : 2279-2289, 2022.
PubMed
30) Nagami Y, Ominami M, Shiba M, et al : The five-year survival rate after endoscopic submucosal dissection for superficial esophageal squamous cell neoplasia. Dig Liver Dis 49 : 427-433, 2017.
PubMed
31) Qi ZP, Chen T, Li B, et al : Endoscopic submucosal dissection for early esophageal cancer in elderly patients with relative indications for endoscopic treatment. Endoscopy 50 : 839-845, 2018.
 
32) Yamashina T, Ishihara R, Nagai K, et al : Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol 108 : 544-551, 2013.
PubMed
33) Katada C, Muto M, Momma K, et al : Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae-a multicenter retrospective cohort study. Endoscopy 39 : 779-783, 2007.
PubMed
34) Takahashi K, Hashimoto S, Mizuno KI, et al : Management decision based on lymphovascular involvement leads to favorable outcomes after endoscopic treatment of esophageal squamous cell carcinoma. Endoscopy 50 : 662-670, 2018.
PubMed
35) Nakajo K, Abe S, Oda I, et al : Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma : a multicenter retrospective study. J Gastroenterol 54 : 871-880, 2019.
PubMed
36) Oda I, Shimizu Y, Yoshio T, et al : Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer : a secondary analysis of the Japan Esophageal Cohort study. Endoscopy 52 : 967-975, 2020.
PubMed
37) Tanaka T, Ueno M, Iizuka T, et al : Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma. Dis Esophagus 32 : doz023, 2019.
PubMed
38) Koterazawa Y, Nakamura T, Oshikiri T, et al : A comparison of the clinical outcomes of esophagectomy and chemoradiotherapy after noncurative endoscopic submucosal dissection for esophageal squamous cell carcinoma. Surg Today 48 : 783-789, 2018.
PubMed
P.346 掲載の参考文献
1) Sgourakis G, Gockel I, Lang H : Endoscopic and surgical resection of T1a/T1b esophageal neoplasms : a systematic review. World J Gastroenterol. 19 : 1424-1437, 2013
 
2) Kato K, Ito Y, Nozaki I, et al : Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 161 : 1878-1886, 2021
 
3) Akutsu Y, Kato K, Igaki H, et al : The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer : From the Results of JCOG0502, a Prospective Multicenter Study. Ann Surg 264 : 1009-1015, 2016
PubMed
4) Kato K, Muro K, Minashi K, et al : Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma : JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81 : 684-690, 2011
PubMed
5) Minsky BD, Pajak TF, Ginsberg RJ, et al : INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer : high-dose versus standard-dose radiation therapy. J Clin Oncol 20 : 1167-1174, 2002
PubMed
6) Hulshof MCCM, Geijsen ED, Rozema T, et al : Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol 39 : 2816-2824, 2021
 
7) Takeuchi H, Ito Y, Machida R, et al : A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys. 114 : 454-462, 2022
PubMed
8) Ji Y, Du X, Zhu W, et al : Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer : A Multicenter Randomized Phase 3 Clinical Trial. JAMA Oncol 7 : 1459-1466, 2021
 
P.352 掲載の参考文献
1) Takeuchi H, Fujii H, Ando N, et al : Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg 249 : 757-763, 2009.
PubMed
2) Akutsu Y, Kato K, Igaki H, et al : The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer : From the Results of JCOG0502, a Prospective Multicenter Study. Ann Surg 264 : 1009-1015, 2016.
PubMed
3) Kurokawa Y, Takeuchi H, Doki Y, et al : Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors : A Prospective Nationwide Multicenter Study. Ann Surg 274 : 120-127, 2021.
PubMed
4) Matsuda S, Takeuchi H, Kawakubo H, et al : Three-field lymph node dissection in esophageal cancer surgery. J Thorac Dis 9 (Suppl 8) : S731-S740, 2017.
 
5) Torek F : The first successful case of resection of the thoracic portion of the oesophagus for carcinoma. Surg Gynecol Obstet 16 : 614-617, 1913.
 
6) Sannohe Y, Hiratsuka R, Doki K : Lymph node metastases in cancer of the thoracic esophagus. Am J Surg 141 : 216-218, 1981.
PubMed
7) Fujita H, Kakegawa T, Yamana H, e t al : Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 222 : 654-662, 1995.
 
8) Ando N, Ozawa S, Kitagawa Y, et al : Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232 : 225-232, 2000.
PubMed
9) Altorki N, Kent M, Ferrara C, et al : Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 236 : 177-183, 2002.
PubMed
10) Cuschieri A, Shimi S, Banting S : Endoscopic oesophagectomy through a right thoracoscopic approach. J R Coll Surg Edinb 37 : 7-11, 1992.
PubMed
11) Biere SS, van Berge Henegouwen MI, Maas KW, et al : Minimally invasive versus open oesophagectomy for patients with oesophageal cancer : a multicentre, open-label, randomised controlled trial. Lancet 379 : 1887-1892, 2012.
PubMed
12) Mariette C, Markar SR, Dabakuyo-Yonli TS, et al : Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. N Engl J Med 380 : 152-162, 2019
PubMed
13) Kataoka K, Takeuchi H, Mizusawa J, et al : A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer : Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol 46 : 174-177, 2016.
 
14) Tachimori Y, Kanamori N, Uemura N, et al : Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. The Journal of thoracic and cardiovascular surgery 137 : 49-54, 2009.
PubMed
15) Ishiyama K, Oguma J, Kubo K, et al : Salvage minimally invasive esophagectomy after definitive chemoradiotherapy for esophageal cancer can improve postoperative complications compared with salvage open esophagectomy. Surg Endosc 36 : 3504-3510, 2022.
PubMed
16) van der Sluis PC, van der Horst S, May AM, et al : Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer : A Randomized Controlled Trial. Ann Surg 269 : 621-630, 2019.
PubMed
17) Kato K, Ito Y, Daiko H, et al : A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40 (suppl 4) : 238-238, 2022.
 
18) Katada C, Hara H, Fujii H, et al : A phase II study of chemoselection with docetaxel, cisplatin, and 5-fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial). J Clin Oncol 39 (suppl 15) : 4027, 2021.
 
P.358 掲載の参考文献
1) Watanabe M, Tachimori Y, Oyama T, et al : Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus 18 : 1-24, 2021.
PubMed
2) Ando N, Iizuka T, Ide H, et al : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus : a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21 : 4592-4596, 2003.
 
3) van Hagen P, Hulshof MC, van Lanschot JJ, et al : Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366 : 2074-2084, 2012.
 
4) Tepper J, Krasna MJ, Niedzwiecki D, et al : Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer : CALGB 9781. J Clin Oncol 26 : 1086-1092, 2008.
PubMed
5) Ando N, Kato H, Igaki H, et al : A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19 : 68-74, 2012.
 
6) Kato K, Ito Y, Daiko H, et al : A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40 (Suppl 4) : 238, 2022.
 
7) Yamamoto S, Kato K, Daiko H, et al : Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma : FRONTiER (JCOG1804E). Future Oncol 16 : 1351-1357, 2020.
PubMed
8) Eyck BM, van Lanschot JJ, Hulshof MC, et al : Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer : The Randomized Controlled CROSS Trial. J Clin Oncol 39 : 1995-2004, 2021.
 
9) Klevebro F, Alexandersson von Dobeln G, Wang N, et al : A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27 : 660-667, 2016.
PubMed
10) Hashimoto J, Kato K, Ito Y, et al : Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. Int J Clin Oncol 24 : 60-67, 2019.
PubMed
11) Hara H, Tahara M, Daiko H, et al : Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104 : 1455-1460, 2013.
PubMed
12) Kato K, Cho BC, Takahashi M, et al : Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 : 1506-1517, 2019.
PubMed
13) Doki Y, Ajani JA, Kato K, et al : Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386 : 449-462, 2022.
PubMed
14) Yamamoto S, Kato K, Daiko H, et al : FRONTiER : A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E) -The short-term results of cohort A and B. J Clin Oncol 39 (Suppl 3) : 202, 2021.
 
15) Matsuda S, Yamamoto S, Kato K, et al. FRONTiER : A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E) -Short-term results for cohorts C and D. J Clin Oncol 40 (Suppl 4) : 286, 2022.
 
16) Ishikawa T, Yasuda T, Okayama T, et al : Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil : A phase II study. Cancer Sci 110 : 3754-3760, 2019.
PubMed
17) Maeda O, Fukaya M, Koike M, et al : Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer : A phase II study. Asia Pac J Clin Oncol 18 : 578-585, 2022.
PubMed
18) Hashimoto H, Abe M, Tokuyama O, et al : Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21 : 242-249, 2020.
 
19) Kadono T, Yamamoto S, Hirose T, et al : Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus 20 : 109-115, 2023.
PubMed
P.365 掲載の参考文献
1) Brierley JD, Gospodarowicz MK, Wittekind C (eds) : TNM Classification of Malignant Tumours, 8th ed., John Wiley & Sons, New Jersey, 2017.
 
2) Ishida K, Ando N, Yamamoto S, et al : Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG) Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34 : 615-619, 2004.
PubMed
3) Shinoda M, Ando N, Kato K, et al : Japan Clinical Oncology Group. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106 : 407-412, 2015.
PubMed
4) Ohtsu A, Boku N, Muro K, et al : Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus : J Clin Oncol 17 : 2915-2921, 1999.
PubMed
5) Satake H, Tahara M, Mochizuki S, et al : A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol 78 : 91-99, 2016.
PubMed
6) Tsushima T, Mizusawa J, Sudo K, et al : Japan Esophageal Oncology Group of Japan Clinical Oncology Group (JCOG). Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer : A Supplementary Analysis of JCOG0303. Medicine (Baltimore) 95 : e3699, 2016.
PubMed
7) Takeuchi H, Ito Y, Machida R, et al : A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909). Int J Radiat Oncol Biol Phys 114 : 454-462, 2022.
PubMed
8) Vermorken JB, Remenar E, van Herpen C, et al : Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357 : 1695-1704, 2007.
PubMed
9) Nakamura K, Kato K, Igaki H, et al : Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Onco 43 : 752-755, 2013.
 
10) Kataoka K, Tsushima T, Mizusawa J, et al : A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer : rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study). Jpn J CLin Oncol 45 : 494-498, 2015.
PubMed
11) Yokota T, Kato K, Hamamoto Y, et al : Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Br J Cancer 115 : 1328-1334, 2016.
PubMed
12) Yokota T, Kato K, Hamamoto Y, et al : A 3-Year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol 27 : 460-467, 2020.
PubMed
13) Terada M, Hara H, Daiko H, et al : Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510 : TRIANgLE). Jpn J Clin Oncol 49 : 1055-1060, 2019.
PubMed
14) Crosby T, Hurt CN, Falk S, et al : Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1) : a multicentre, phase 23 randomised trial. Lancet Oncol 14 : 627-637, 2013.
 
15) Suntharalingam M, Winter K, Ilson D, et al : Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer : The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. JAMA Oncol 3 : 1520-1528, 2017.
PubMed
16) David R. Spigel, Corinne Faivre-Finn, Jhanelle E, et al : Five-Year Survival Outcomes From the PACIFIC Trial : Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 40 : 1301-1311, 2022.
PubMed
P.372 掲載の参考文献
1) Bleiberg H, Conroy T, Paillot B, et al : Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33 : 1216-1220, 1997
PubMed
2) Iizuka T, Kakegawa T, Ide H, et al : Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22 : 172-176, 1992
PubMed
3) Hayashi K, Ando N, Watanabe H, et al : Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus : a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 31 : 419-423, 2001
PubMed
4) Lorenzen S, Schuster T, Porschen R, et al : Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus : a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20 : 1667-1673, 2009
PubMed
5) Moehler M, Maderer A, Thuss-Patience PC, et al : Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer : a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Ann Oncol 31 : 228-235, 2020
PubMed
6) Honda M, Miura A, Izumi Y, et al : Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus 23 : 641-645, 2010
PubMed
7) Hironaka S, Tsubosa Y, Mizusawa J, et al : Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 105 : 1189-1195, 2014
PubMed
8) Dutton SJ, Ferry DR, Blazeby JM, et al : Gefitinib for oesophageal cancer progressing after chemotherapy (COG) : a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol 15 : 894-904, 2014
PubMed
9) Kato K, Tahara M, Hironaka S, et al : A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67 : 1265-1272, 2011
PubMed
10) Muro K, Hamaguchi T, Ohtsu A, et al : A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15 : 955-959, 2004
PubMed
11) Kudo T, Hamamoto Y, Kato K, et al : Nivolumab treatment for oesophageal squamous-cell carcinoma : an open-label, multicentre, phase 2 trial. Lancet Oncol 18 : 631-639, 2017
PubMed
12) Shah MA, Kojima T, Hochhauser D, et al : Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus : The Phase 2 KEYNOTE-180 Study. JAMA Oncol 5 : 546-550, 2019
PubMed
13) Kato K, Cho BC, Takahashi M, et al : Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3) : a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20 : 1506-1517, 2019
PubMed
14) Kojima T, Shah MA, Muro K, et al : Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 38 : 4138-4148, 2020
PubMed
15) 日本食道学会 (編) : 食道癌診療ガイドライン 2022年版, 金原出版, 東京, 2022.
 
16) Shen L, Kato K, Kim SB, et al : Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302) : A Randomized Phase III Study. J Clin Oncol 40 : 3065-3076, 2022
 
17) Huang J, Xu J, Chen Y, et al : Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT) : a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 21 : 832-842, 2020
PubMed
18) Sun JM, Shen L, Shah MA, et al : Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590) : a randomised, placebo-controlled, phase 3 study. Lancet 398 : 759-771, 2021
PubMed
19) Doki Y, Ajani JA, Kato K, et al : Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386 : 449-462, 2022
PubMed
20) Luo H, Lu J, Bai Y, et al : Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma : The ESCORT-1st Randomized Clinical Trial. JAMA 326 : 916-925, 2021
PubMed
21) Yoon H, Kato K, Raymond E, et al : RATIONALE-306 : Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology 33 : S375, 2022
PubMed
22) Lu Z, Wang J, Shu Y, et al : Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15) : multicentre, randomised, double blind, phase 3 trial. BMJ 377 : e068714, 2022
PubMed
23) Wang ZX, Cui C, Yao J et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06) : A multi-center phase 3 trial. Cancer Cell 40 : 277-288 : e273, 2022
 

【研究】

P.381 掲載の参考文献
1) Haqa A, Goodyeara B, Ameen D, et al : Strat-M(R) synthetic membrane : Permeability comparison to human cadaver skin. International Journal of Pharmaceutics 547 : 432-437, 2018.
 
2) Uchida T, Kadhum WR, Kanai S, et al : Prediction of skin permeation by chemical compounds using the artificial membrane, Strat-M(TM). European Journal of Pharmaceutical Sciences 67 : 113-118, 2015.
 
3) Klebeko J, Ossowicz-Rupniewska P, Nowak A, et al : Permeability of Ibuprofen in the Form of Free Acid and Salts of L-Valine Alkyl Esters from a Hydrogel Formulation through Strat-M(TM) Membrane and Human Skin. Materials 14 : 6678, 2021.
 
4) Ossowicz-Rupniewska P, Nowak A, Klebeko J, et al : Assessment of the Effect of Structural Modification of Ibuprofen on the Penetration of Ibuprofen from Pentravan(R) (Semisolid) Formulation Using Human Skin and a Transdermal Diffusion Test Model. Materials 14 : 6808, 2021.
 
5) Funami T, Nakauma M : Instrumental food texture evaluation in relation to human perception. Food Hydrocolloids 124 : 107253, 2022.
 
6) Tai A, Bianchini R, Jachowicz J : Texture analysis of cosmetic/pharmaceutical raw materials and formulations. International Journal of Cosmetic Science 36 (4) : 291-304, 2014.
PubMed
7) 照喜名孝之, 近藤啓 : 貼付剤の製剤学的特性を識別可能とする評価法に関する検討. 医学と薬学 79 (5) : 659-665, 2022.
Medical*Online
8) Tokuoka Y, Suzuki M, Ochiai A, et al : Enhancement in Skin Permeation of 5-Aminolevulinic Acid Using l-Menthol and its Derivatives. Drug Development and Industrial Pharmacy 34 (6) : 596-601, 2008.
 
9) Cilurzo F, Gennari C G, Minghetti P : Adhesive properties : a critical issue in transdermal patch development. Expert Opinion on Drug Delivery 9 (1) : 33-45, 2012.
PubMed

【Diagnosis】

P.403 掲載の参考文献
1) 森昌朋 : 推薦のことば. 田上哲也, 伊藤公一, 成瀬光栄 (編), 甲状腺疾患診療マニュアル 改訂第3版, pxiv, 診断と治療社, 東京, 2020.
 
2) 杉野公則 : 甲状腺疾患の頻度と発見のきっかけ. 伊藤公一, 杉野公則 (編), 伊藤病院 甲状腺疾患を極める, pp.14-18, 新興医学出版社, 東京, 2018.
 
3) 西野道夫, 村上正巳 : 抗サイログロブリン抗体, 抗ミクロゾーム抗体. Nippon Rinsho 63 (8) : 280-283, 2005.
 
4) 西野道夫, 村上正巳 : 抗甲状腺ペルオキシダーゼ抗体. Nippon Rinsho 63 (8) : 284-287, 2005.
 
5) 日本甲状腺学会 編 : 4. 甲状腺疾患の診断 (3) 甲状腺自己抗体, サイログロブリン. 甲状腺専門医ガイドブック 改訂第2版, pp.63-67, 診断と治療社, 東京, 2018.
 
6) 上條桂一, 菊池みゆき, 竹並健, 他 : 全自動電気化学発光免疫測定装置cobas e411を用いたECLIA (electrochemiluminescence immunoassay) 法 (ロシュ・ダイアグノスティックス株式会社) で測定したTgAbおよびTPOAb値による橋本病の血清診断と病理学的診断との相関. 医学と薬学 61 (5) : 739-746, 2009.
Medical*Online
7) 森田新二, 西原永潤, 窪田純久, 他 : 抗サイログロブリン抗体測定キット「エクルーシス試薬Anti-Tg」および抗甲状腺ペルオキシダーゼ抗体測定キット「エクルーシス試薬Anti-TPO」の検討-病理組織像との対比から得られたROC曲線を用いたカットオフ値の設定と従来法の比較-. 医学と薬学 55 (5) : 775-782, 2006.
Medical*Online
8) 吉村弘, 浜田昇, 井上穣, 他 : 化学発光酵素免疫測定法による抗サイログロブリン抗体および抗甲状腺ペルオキシダーゼ抗体測定キットの臨床的検討. 医学と薬学 44 (3) : 569-573, 2000.
Medical*Online
9) 涌井佳美, 鈴木尚子, 上道文昭, 他 : TRAb第3世代測定試薬の基礎的, 臨床的検討ECLIA法による「エクルーシス試薬TRAb」. 東京医科大学雑誌 69 (3) : 382-388, 2011.
Medical*Online
10) 北川亘, 宮崎直子, 田中克昌, 他 : ルミパルス(R) L2400を用いたルミパルスプレスト(R) 甲状腺関連項目 (TSH, FT3, FT4, T3, T4, TgAb, TPOAb, TRAb) の臨床的評価. 医学と薬学 78 (10) : 1233-1246, 2021.
Medical*Online
11) 吉村弘, 村上司, 宮崎直子, 他 : 抗TSHレセプターヒトモノクローナル抗体 (M22) を用いた電気化学発光免疫測定法 (ECLIA) による抗TSHレセプター抗体 (TRAb) 全自動測定試薬の基礎的, 臨床的性能評価. 医学と薬学 59 (6) : 1111-1120, 2008.
Medical*Online
12) 向笠浩司 : 甲状腺機能低下症の診断 橋本病を中心に. 伊藤公一, 杉野公則 (編), 伊藤病院 甲状腺疾患を極める, pp.65-69, 新興医学出版社, 東京, 2018.
 
13) 松田いずみ, 山本晶子, 村上司, 他 : TSHレセプター抗体 (TRAb) 第三世代全自動測定試薬の比較検討-電気化学発光免疫測定法 (ECLIA法) および蛍光酵素免疫測定法 (FEIA法) の性能比較試験-. 医学と薬学 71 (5) : 877-884, 2014.
Medical*Online
14) 西原永潤, 森田新二, 工藤工, 他 : 電気化学発光免疫測定法を用いた抗サイログロブリン抗体, 抗甲状腺ペルオキシダーゼ抗体測定 (エクルーシス試薬Anti-Tg, エクルーシス試薬Anti-TPO) の臨床的検討. 医学と薬学 56 (3) : 411-418, 2006.
Medical*Online
15) 峯尾真澄, 池田直子, 河本知恵, 他 : 抗サイログロブリン抗体測定キット「アーキテクト(R) ・Tg抗体」ならびに抗甲状腺ペルオキシダーゼ抗体測定キットアーキテクト(R) ・TPO抗体」の検討. 医学と薬学 68 (6) : 1013-1024, 2012.
 
16) 武市藍, 青木智之, 常川勝彦, 他 : 抗サイログロブリン抗体 (TgAb) および抗甲状腺ペルオキシダーゼ抗体 (TPOAb) 測定キットの検討-3法 (RIA法, FEIA法, ECLIA法) の比較-. 医学と薬学 62 (4) : 791-800, 2009.
Medical*Online
17) 古田島伸雄, 小林良乃, 町田哲男, 他 : M22を用いた「ルミパルスプレストTRAb」によるTRAb測定法の基礎的検討. 医学と薬学 67 (6) : 911-916, 2012.
Medical*Online
18) 山田徹, 松元雄太, 白川拓真, 他 : 化学発光免疫測定装置を用いた新規第三世代TRAb測定試薬の開発と性能評価. 医学と薬学 78 (5) : 615-626, 2021.
Medical*Online
19) 三橋知明 : 甲状腺検査の最近の進歩-抗TSH受容体抗体をめぐって-. 日本内科学会雑誌 99 (4) : 700-706, 2010.
 
P.414 掲載の参考文献
1) 高橋勝幸 : 6) 浸透圧計. Medical Technology 34 (13) : 1357-1360, 2006.
Medical*Online
2) 斎藤史郎 : 浸透圧の測定とその臨床的意義. 生物試料分析 3 (2) : 1-9, 1981.
 
3) 増田健太, 津和光博, 赤井洋子, 他 : 自動浸透圧測定装置オズモステーションOM-6060の基礎的検討. 機器・試薬 30 (4) : 383-391, 2007.
 
4) 金子朋広 : 尿浸透圧の意味と読み方. 腎と透析 90 (5) : 671-675, 2021.
Medical*Online
P.422 掲載の参考文献
1) World health statistics 2022 : monitoring health for the SDGs, sustainable development goals : 19 May 2022.
 
2) McMahon BJ : Natural history of chronic hepatitis B. Clin Liver Dis 14 : 381-396, 2010.
PubMed
3) Okamoto H, Tsuda F, Sakugawa H, et al : Typing hepatitis B virus by homology in nucletide sequnence : comparison of surface antigen subtypes. J Gen Virol 69 : 2575-2583, 1988.
 
4) 日本肝臓学会肝炎診療ガイドライン作成委員会 : B型肝炎治療ガイドライン (第3.4版). 2021年5月.
 
5) Chan HL, Wong VW, Wong GL, et al : A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 52 : 1232-1241, 2010.
PubMed
6) Vincent Rijckborst, Bettina E. Hansen, Yilmaz Cakaloglu, et al : Early On-Treatment Prediction of Response to Peginterferon Alfa-2a for HBeAg-Negative Chronic Hepatitis B Using HBsAg and HBV DNA Levels. Hepatology 52 : 454-461, 2010.
PubMed
7) 田中榮司, 松本晶博, 鈴木義之, 他 : 核酸アナログ薬中止に伴うリスク回避のための指針 2012-厚生労働省「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する研究」の報告-. 肝臓 53 : 237-242, 2012.
 
8) 田中靖人 : ウイルス肝炎診療の現状と課題 B型肝炎の最新治療-創薬研究から臨床応用へ-. 日本消化器病学会雑誌 119 : 802-811, 2022.
 
9) Man-Fung Yuen, Tarik Asselah, Ira M. Jacobson, et al : Efficacy and Safety of the siRNA JNJ-3989 and/or the Capsid Assembly Modulator JNJ-6379 for the Treatment of Chronic Hepatitis B Virus Infection, Results From the Phase 2b REEF-1 Study, Late-breaking oral presentation at the American Association for the Study of Liver Diseases. The Liver Meeting. Nov 12-15, 2021.
PubMed
10) 山崎一美, 長岡進矢, 八橋弘 : 各種抗ウイルス療法別HBs抗原量の推移の検討. 肝臓 58 : A571, 2017.
 
P.429 掲載の参考文献
1) Lipsitch M, Swerdlow DL, Finelli L : Defining the Epidemiology of Covid-19 - Studies Needed. N Engl J Med 382 (13) : 1194-1196, 2020.
PubMed
2) 貞升健志, 吉村和久 : 新型コロナウイルス感染症に対する検査・診断. 保健医療科学 71 (4) : 314-323, 2022.
 
3) 厚生労働省 : 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 (第6版) https://anshin.pref.tokushima.jp/med/experts/docs/2022122700123/files/2.pdf
 
4) Hayden MK, Hanson KE, Englund JA, et al : The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 : Antigen Testing. Clin Infect Dis. 2023 Jan 22.
 
5) Kawser Z, Hossain M, Suliman S, et al : An Assessment of a Rapid SARS-CoV-2 Antigen Test in Bangladesh. Am J Trop Med Hyg 107 (4) : 845-849, 2022.
PubMed
6) Morishima M, Kimura M, Sakoh T, et al : Universal admission screening for COVID-19 using quantitative antigen testing and questionnaire screening to prevent nosocomial spread. PLoS One 12022 Nov 10 ; 17 (11).
 
7) Hirotsu Y, Sugiura H, Maejima M, et al : Comparison of Roche and Lumipulse quantitative SARS-CoV-2 antigen test performance using automated systems for the diagnosis of COVID-19. Int J Infect Dis 108 : 263-2690, 2021.
PubMed
8) Kobayashi R, Murai R, Asanuma K, et al : Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen. J Infect Chemother 27 (6) : 800-807, 2021.
PubMed
9) Nomoto H, Yamamoto K, Isaka E, et al : Potential usage of anterior nasal sampling in clinical practice with three rapid antigen tests for SARS-CoV-2. J Infect Chemother 29 (1) : 15-19, 2023.
PubMed
10) Ishii T, Sasaki M, Yamada K, et al : Immunochromatography and chemiluminescent enzyme immunoassay for COVID-19 diagnosis. J Infect Chemother 27 (6) : 915-918, 2021.
PubMed
11) Seitz T, Lickefett B, Traugott M, et al : Evaluation of Five Commercial SARS-CoV-2 Antigen Tests in a Clinical Setting. J Gen Intern Med 37 (6) : 1494-1500, 2022.
 
12) Kim KS, Ejima K, Iwanami S, et al : A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol 19 (3) e3001128, 2021.
 
13) Crozier A, Rajan S, Buchan I, et al : Put to the test : use of rapid testing technologies for covid-19. BMJ 372 : n208, 2021.
 

書評

最近チェックした商品履歴

Loading...